Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELIVER trial of dapagliflozin in heart failure with preserved ejection fraction
NL-OMON49973Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Primary composite endpoint. Started Nov 2018; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON49973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49973.